MedTrace Logo

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

NCT00741689 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose of this study is to assess safety and tolerability of AZD1656 after single ascending oral doses in Japanese healthy male subjects

Conditions

  • Healthy Volunteers

Interventions

DRUG

AZD1656

Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD Prof · AstraZeneca R&D Mölndal

  • Mark Yen, MD · California Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00741689 on ClinicalTrials.gov